Sandro Pignata

35.1k total citations · 5 hit papers
434 papers, 10.6k citations indexed

About

Sandro Pignata is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, Sandro Pignata has authored 434 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 233 papers in Reproductive Medicine, 199 papers in Oncology and 95 papers in Surgery. Recurrent topics in Sandro Pignata's work include Ovarian cancer diagnosis and treatment (228 papers), Endometrial and Cervical Cancer Treatments (91 papers) and PARP inhibition in cancer therapy (80 papers). Sandro Pignata is often cited by papers focused on Ovarian cancer diagnosis and treatment (228 papers), Endometrial and Cervical Cancer Treatments (91 papers) and PARP inhibition in cancer therapy (80 papers). Sandro Pignata collaborates with scholars based in Italy, United States and Spain. Sandro Pignata's co-authors include Bruno Daniele, Carmela Pisano, Sabrina Chiara Cecere, Giovanni Scambia, Francesco Izzo, Francesco Fiore, Paolo Vallone, Domenica Lorusso, Steven A. Curley and Nicoletta Colombo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Sandro Pignata

401 papers receiving 10.3k citations

Hit Papers

Radiofrequency Ablation o... 1999 2026 2008 2017 1999 2010 2018 2019 2023 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Radiofrequency Ablation of Unresectable Primary and Metastatic Hepatic Malignancies
    1999 856 citations Sandro Pignata et al. profile →
  2. Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
    2010 410 citations Éric Pujade-Lauraine, Uwe Wagner et al. Journal of Clinical Oncology profile →
  3. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer
    2018 340 citations David Cibula, Sandro Pignata et al. International Journal of Gynecological Cancer profile →
  4. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
    2019 259 citations Nicoletta Colombo, Andreas du Bois et al. International Journal of Gynecological Cancer profile →
  5. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
    2023 220 citations Domenica Lorusso, Ana Oaknin et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Sandro Pignata 4.4k 4.2k 2.4k 2.4k 2.0k 434 10.6k
Gordon Rustin 5.3k 1.2× 5.1k 1.2× 4.0k 1.7× 3.4k 1.4× 1.3k 0.6× 245 16.0k
Jonathan A. Ledermann 9.2k 2.1× 8.0k 1.9× 4.9k 2.0× 3.1k 1.3× 2.7k 1.4× 295 17.4k
Robert A. Burger 4.6k 1.1× 9.1k 2.2× 3.6k 1.5× 4.4k 1.9× 3.7k 1.9× 202 14.8k
Carol Aghajanian 6.1k 1.4× 7.5k 1.8× 3.6k 1.5× 3.2k 1.3× 4.3k 2.2× 425 15.3k
S. Diane Yamada 2.2k 0.5× 1.9k 0.4× 3.1k 1.3× 1.3k 0.6× 1.8k 0.9× 102 8.0k
Christian Marth 5.3k 1.2× 3.1k 0.7× 5.8k 2.4× 1.6k 0.7× 2.2k 1.1× 411 14.0k
Alexander Reinthaller 2.2k 0.5× 2.4k 0.6× 1.3k 0.5× 2.1k 0.9× 2.5k 1.3× 273 7.2k
Ana Oaknin 6.8k 1.6× 4.4k 1.0× 3.8k 1.5× 1.8k 0.8× 3.2k 1.6× 320 12.7k
Gunnar B. Kristensen 4.3k 1.0× 7.6k 1.8× 3.6k 1.5× 3.8k 1.6× 4.4k 2.3× 266 14.7k
Mark F. Brady 3.7k 0.8× 8.4k 2.0× 2.0k 0.8× 3.7k 1.5× 3.9k 2.0× 111 12.0k

Countries citing papers authored by Sandro Pignata

Since Specialization
Citations

This map shows the geographic impact of Sandro Pignata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandro Pignata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandro Pignata more than expected).

Fields of papers citing papers by Sandro Pignata

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandro Pignata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandro Pignata. The network helps show where Sandro Pignata may publish in the future.

Co-authorship network of co-authors of Sandro Pignata

This figure shows the co-authorship network connecting the top 25 collaborators of Sandro Pignata. A scholar is included among the top collaborators of Sandro Pignata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandro Pignata. Sandro Pignata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bartoletti, Michele, Marcella Montico, Domenica Lorusso, et al.. (2024). Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis. Cancer Treatment Reviews. 125. 102701–102701. 18 indexed citations
3.
Palaia, Innocenza, Giuseppe Caruso, Violante Di Donato, et al.. (2024). Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey. Journal of Gynecologic Oncology. 35(3). e70–e70. 4 indexed citations
4.
Cecere, Sabrina Chiara, Marilena Di Napoli, Jole Ventriglia, et al.. (2024). Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options. Critical Reviews in Oncology/Hematology. 204. 104533–104533. 7 indexed citations
5.
Lorusso, Domenica, et al.. (2024). Venous Thromboembolism Prophylaxis in Gynecologic Oncology: A MITO-MaNGO Survey. Diagnostics. 14(11). 1159–1159. 1 indexed citations
6.
Passarelli, Anna, Jole Ventriglia, Carmela Pisano, et al.. (2023). The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer. Frontiers in Oncology. 12. 1088962–1088962. 5 indexed citations
7.
8.
Barcellini, Amelia, Tullio Golia D’Augè, Vincenzo Dario Mandato, et al.. (2023). Primary neuroendocrine neoplasms of the vulva: A review of the MITO rare cancer group. Critical Reviews in Oncology/Hematology. 193. 104201–104201. 1 indexed citations
9.
Malapelle, Umberto, Fabio Pagni, Filippo Fraggetta, et al.. (2023). Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group. Critical Reviews in Oncology/Hematology. 193. 104217–104217. 7 indexed citations
10.
Scaglione, Giovanni Luca, Sandro Pignata, Carmela Paolillo, et al.. (2023). Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay. International Journal of Molecular Sciences. 24(23). 17095–17095. 4 indexed citations
11.
Castro, Elena, Douglas Laird, Shuang G. Zhao, et al.. (2023). 1815P Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1. Annals of Oncology. 34. S983–S984. 2 indexed citations
12.
13.
Concin, Nicole, Manish R. Patel, Vicky Makker, et al.. (2022). 2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies. International Journal of Gynecological Cancer. 32. A185–A185.
14.
15.
Barcellini, Amelia, Giorgia Mangili, Andrei Fodor, et al.. (2022). Granulosa cell tumors (GCTs) of the ovary: What is the role of radiotherapy?. Critical Reviews in Oncology/Hematology. 181. 103889–103889. 5 indexed citations
16.
Romero, Ignacio, José Antonio López‐Guerrero, & Sandro Pignata. (2021). Real-world experience with trabectedin for the treatment of recurrent ovarian cancer. Expert Review of Anticancer Therapy. 21(10). 1089–1095. 6 indexed citations
17.
Califano, Daniela, Daniela Russo, Giosuè Scognamiglio, et al.. (2020). Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. Cells. 9(4). 903–903. 2 indexed citations
18.
Mangili, Giorgia, Cristina Sigismondi, Domenica Lorusso, et al.. (2016). The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study. Annals of Oncology. 28(2). 333–338. 54 indexed citations
19.
Oza, Amit M., Sandro Pignata, Andrés Poveda, et al.. (2015). Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. Journal of Clinical Oncology. 33(31). 3576–3582. 82 indexed citations
20.
Pujade-Lauraine, Éric, Uwe Wagner, Val Gebski, et al.. (2010). Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. Journal of Clinical Oncology. 28(20). 3323–3329. 410 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gordon Rustin Breakdown of academic impact, for papers by Jonathan A. Ledermann Breakdown of academic impact, for papers by Robert A. Burger Breakdown of academic impact, for papers by Carol Aghajanian Breakdown of academic impact, for papers by S. Diane Yamada Breakdown of academic impact, for papers by Christian Marth Breakdown of academic impact, for papers by Alexander Reinthaller Breakdown of academic impact, for papers by Ana Oaknin Breakdown of academic impact, for papers by Gunnar B. Kristensen Breakdown of academic impact, for papers by Mark F. Brady
Rankless by CCL
2026